Source: Pharamceutical Technology

MBT: Regulatory and IP strategies for live biotherapeutic products

On September 6, the Microbiome Therapeutics US conference focused on overcoming regulatory challenges and strategies to gain intellectual property (IP)...Read More...The post Regulatory and IP strategies for live biotherapeutic products appeared first on Pharmaceutical Technology.

Read full article »
MBT's Competitors | MBT's News | MBT's Financials
Stay up-to-date with the latest news on MicroBiome Therapeutics, LLC
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Dale R. Pfost's photo - Co-Founder & CEO of MicroBiome Therapeutics, LLC

Co-Founder & CEO

Dale R. Pfost

CEO Approval Rating

91/100

Read more
Stay up-to-date with the latest news on MicroBiome Therapeutics, LLC